Alzheimer's Disease Trial, By Invitation
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with Mild Cognitive Impairment (MCI), or who have not yet been diagnosed but are showing memory changes as measured by a test called the MoCA.
- People whose MoCA test score falls between 18 and 28 (inclusive).
- People aged between 55 and 80 years (inclusive).
- People who have a "study partner" (such as a family member or friend) who is willing to take part by providing information about the person, and who has roughly weekly contact with them — whether in person, by phone, or electronically — with enough contact that the trial investigator feels the study partner can speak meaningfully about how the person manages day-to-day.
- Group A: People who have a clinical memory assessment appointment already scheduled at Parkwood Institute within 18 months of the study start date.
- Group B: People who have already had a clinical memory assessment appointment at Parkwood Institute within 18 months of the study start date.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose memory or thinking difficulties are thought to be caused by a condition other than Alzheimer's disease — for example, conditions such as frontotemporal dementia, Lewy body disease, Parkinson's disease, stroke-related changes, normal pressure hydrocephalus, head injury, or drug or alcohol use.
- People who have a neurological, psychiatric, or medical condition that is associated with a long-term risk of significant cognitive decline or dementia, including (but not limited to) pre-symptomatic Huntington's disease, multiple sclerosis, Parkinson's disease, Down syndrome, active drug or alcohol misuse, schizophrenia, schizoaffective disorder, bipolar disorder, or a current episode of major depression.
- People who currently have, or have had within the past 2 years, a psychiatric diagnosis or symptoms — such as hallucinations, major depression, or delusions — that in the investigator's opinion could interfere with study procedures.
- People who have had epilepsy, seizures, or unexplained blackouts (other than a simple faint) within the 10 years before the screening visit.
- People who have had a malignant cancer within the past 3 years (skin cancers such as basal cell or squamous cell carcinoma in situ are excepted).
- Women who are able to become pregnant, or who are currently breastfeeding.
- People who would need sedation in order to complete a PET scan.
- People who are unable to complete the study assessments in the English language.
- People who are unable to provide their own consent to participate.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Where this trial is recruiting
Primary endpoints
Determine the feasibility of integrating a CSF biomarker into diagnostic decision making for AD.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 10 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.